F
Frank G. Haluska
Researcher at ARIAD Pharmaceuticals, Inc.
Publications - 158
Citations - 24888
Frank G. Haluska is an academic researcher from ARIAD Pharmaceuticals, Inc.. The author has contributed to research in topics: Ponatinib & Melanoma. The author has an hindex of 57, co-authored 157 publications receiving 23423 citations. Previous affiliations of Frank G. Haluska include Takeda Pharmaceutical Company & Wistar Institute.
Papers
More filters
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F. Stephen Hodi,Martin C. Mihm,Robert J. Soiffer,Frank G. Haluska,Marcus O. Butler,Michael V. Seiden,Thomas A. Davis,Rochele Henry-Spires,Suzanne MacRae,Ann Willman,Robert F. Padera,Michael T. Jaklitsch,Sridhar Shankar,Teresa C. Chen,Alan J. Korman,James P. Allison,Glenn Dranoff +16 more
TL;DR: Findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients.
Journal ArticleDOI
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jorge E. Cortes,Dong-Kee Kim,Javier Pinilla-Ibarz,P. le Coutre,Ronald Paquette,Charles Chuah,F. E. Nicolini,Jane F. Apperley,Hanna Jean Khoury,Moshe Talpaz,John F. DiPersio,Daniel J. DeAngelo,Elisabetta Abruzzese,Delphine Rea,Michele Baccarani,Martin C. Müller,Carlo Gambacorti-Passerini,Stephane Wong,Stephanie Lustgarten,Victor M. Rivera,Timothy P. Clackson,Christopher D. Turner,Frank G. Haluska,François Guilhot,Michael W. Deininger,Andreas Hochhaus,Timothy P. Hughes,J. M. Goldman,Neil P. Shah,Hagop M. Kantarjian +29 more
TL;DR: Ponatinib had significant antileukemic activity across categories of disease stage and mutation status and were durable; the estimated rate of a sustained major cytogenetic response of at least 12 months was 91%.
Journal ArticleDOI
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Jorge E. Cortes,Hagop M. Kantarjian,Neil P. Shah,Dale L. Bixby,Michael J. Mauro,Ian W. Flinn,Thomas O'Hare,Thomas O'Hare,Simin Hu,Narayana I. Narasimhan,Victor M. Rivera,Tim Clackson,Christopher D. Turner,Frank G. Haluska,Brian J. Druker,Michael W. Deininger,Michael W. Deininger,Moshe Talpaz +17 more
TL;DR: Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations.
Journal ArticleDOI
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. Stephen Hodi,Marcus O. Butler,Darryl A. Oble,Michael V. Seiden,Michael V. Seiden,Frank G. Haluska,Andrea Kruse,Suzanne MacRae,Marybeth Nelson,Christine Canning,Israel Lowy,Alan J. Korman,David B. Lautz,Sara Russell,Michael T. Jaklitsch,Nikhil H. Ramaiya,Teresa C. Chen,Donna Neuberg,James P. Allison,Martin C. Mihm,Glenn Dranoff +20 more
TL;DR: It is shown that periodic infusions of anti-CTLA-4 antibodies after vaccination with irradiated, autologous tumor cells engineered to secrete GM-CSF (GVAX) generate clinically meaningful antitumor immunity without grade 3 or 4 toxicity in a majority of metastatic melanoma patients.